Significant growth opportunities in the High Content Screening Market

The overall high content screening market is expected to grow from USD 506.7 million in 2016 to USD 909.0 million by 2022, at a CAGR of 10.3% from 2017 to 2022.

The major factors driving the growth of the HTS market include initiatives undertaken by pharmaceutical and biotechnology companies, increasing R&D spending, technological advancements in HTS, and the availability of government funding and venture capital investments.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391

High Content Screening Market is segmented into following types:

• a href="https://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html">High-content screening

(HCS) is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. High-content screening includes any method used to analyze whole cells or components of cells with a simultaneous readout of several parameters.

• Based on product, the global market is broadly segmented into instruments, consumables, software, services, and accessories. The market for HCS software is expected to grow at the highest CAGR between 2017 and 2022. Among all high content screening products, instrument segment caters to the largest share. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=42710391

Some of The Major Players In High Content Screening Market :

1. GE Healthcare (U.S.)
2. Danaher Corporation (U.S.)
3. Thermo Fisher Scientific, Inc. (U.S.)
4. PerkinElmer, Inc. (U.S.)
5. Tecan Group (Switzerland)
6. BioTek Instruments Inc. (U.S.)
7. Becton, Dickinson and Company (U.S.)
8. Bio-Rad Laboratories (U.S.)

The factors expected to drive the growth of the market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.

By deployment type, the cloud segment to record the highest CAGR during the forecast period

On the basis of application, the high-content screening market is segmented into target identification and validation, primary and secondary screening, toxicity studies, compound profiling, and other applications such as angiogenesis, apoptosis, cell cycle and mitotic index, cell proliferation, endocytosis, protein synthesis, and stem cell differentiation. The primary and secondary screening application segment is expected to grow at highest CAGR during the forecast period. The high growth can primarily be attributed to the wide use of HCS for secondary screening purposes. Growth in the primary and secondary screening segment can also be attributed to the presence of a large number of potential drug candidates for target-specific delivery.

By product, the HCS instruments segment is expected to dominate the market

The HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments. The software segment is expected to register the highest growth during the forecast period. The growth of this market is attributed to the technological advancements in image acquisition, data analysis, and storage capabilities and the need to obtain information on changes in cell morphology through high-quality images.

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth emerging opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.